Tag: PLx Pharma

PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

– Significant Reduction in Operating Expenses – Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022 Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; […]

PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected […]

PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Momentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules Total Net Sales of $8.2 Million in Last Five Months of 2021 Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter 2021 Key Performance Measures Are […]

PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules

— VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition — — VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent with VAZALORE 325 mg — — Findings presented at TCT meeting earlier today — SPARTA, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” […]

PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx’s VAZALORE Specifically Indicated for Secondary Prevention

Aspirin remains an established practice for the prevention of another heart attack or clot-related stroke SPARTA, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective […]

PLx Pharma Inc. Reports Second Quarter 2021 Results and Provides Business Update

–Walmart, Walgreens, Rite Aid, CVS and many other retailers placing VAZALORE on shelves later this month– –VAZALORE launch inventory manufactured and currently shipping to retailers across the country– SPARTA, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused […]